Doxifluridine: Difference between revisions

Doxifluridine
	File:Doxifluridine.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Newer edit →

Revision as of 11:02, 15 February 2025

Overview of the chemotherapeutic agent Doxifluridine

Doxifluridine is an oral prodrug of the chemotherapeutic agent 5-fluorouracil (5-FU), used in the treatment of various cancers. It is designed to enhance the delivery and efficacy of 5-FU by being converted into the active drug within the body.

Mechanism of Action

Doxifluridine is metabolized into 5-fluorouracil by the enzyme thymidine phosphorylase, which is often found in higher concentrations in tumor tissues compared to normal tissues. This selective activation allows for higher concentrations of the active drug in cancerous tissues, potentially reducing systemic toxicity.

Pharmacokinetics

Doxifluridine is administered orally and is absorbed through the gastrointestinal tract. Once absorbed, it is converted into 5-fluorouracil in the liver and tumor tissues. The conversion process is facilitated by the presence of thymidine phosphorylase, which is more abundant in tumor cells, thus providing a targeted approach to chemotherapy.

Clinical Use

Doxifluridine is primarily used in the treatment of colorectal cancer, breast cancer, and gastric cancer. It is often used in combination with other chemotherapeutic agents to enhance its efficacy. The drug's ability to be selectively activated in tumor tissues makes it a valuable option in cancer therapy.

Side Effects

As with many chemotherapeutic agents, doxifluridine can cause a range of side effects. Common side effects include nausea, vomiting, diarrhea, and myelosuppression. Due to its selective activation, it may have a more favorable side effect profile compared to direct administration of 5-fluorouracil.

Related pages

@@ Line 1: / Line 1: @@
-'''Doxifluridine''' is an [[antineoplastic agent]] used in the treatment of cancer. It is a prodrug of [[5-fluorouracil]] (5-FU), a [[pyrimidine analog]] that interferes with [[DNA synthesis]] and [[RNA synthesis]], leading to cell death and thus, has a cytotoxic effect on rapidly dividing cancer cells. Doxifluridine is specifically designed to be activated only within the tumor tissue, aiming to increase the concentration of the active drug in the tumor while minimizing the exposure of healthy tissues to the cytotoxic effects of 5-FU.
+{{Short description|Overview of the chemotherapeutic agent Doxifluridine}}
+{{Drugbox
+| image = Doxifluridine.svg
+| image_size = 250px
+| image_alt = Structural formula of Doxifluridine
+}}
+'''Doxifluridine''' is an oral prodrug of the chemotherapeutic agent [[5-fluorouracil]] (5-FU), used in the treatment of various [[cancer|cancers]]. It is designed to enhance the delivery and efficacy of 5-FU by being converted into the active drug within the body.
 ==Mechanism of Action==
-Doxifluridine is metabolized in the liver to 5-FU, which then inhibits [[thymidylate synthase]], an enzyme crucial for DNA synthesis. This inhibition results in the depletion of [[thymidine triphosphate]] (dTTP), which is necessary for DNA replication and repair. Consequently, the drug induces cell cycle arrest and apoptosis in cancer cells. Additionally, 5-FU is incorporated into RNA, disrupting RNA processing and function.
+Doxifluridine is metabolized into 5-fluorouracil by the enzyme [[thymidine phosphorylase]], which is often found in higher concentrations in tumor tissues compared to normal tissues. This selective activation allows for higher concentrations of the active drug in cancerous tissues, potentially reducing systemic toxicity.
-==Clinical Uses==
-Doxifluridine has been studied and used in the treatment of various types of cancers, including [[breast cancer]], [[gastric cancer]], and [[colorectal cancer]]. Its efficacy and safety profile make it a valuable option in the chemotherapeutic regimen for these malignancies, often in combination with other anticancer agents to enhance therapeutic outcomes.
 ==Pharmacokinetics==
-After oral administration, doxifluridine is rapidly absorbed from the gastrointestinal tract. Its bioactivation to 5-FU primarily occurs in the liver, but also in tumor tissues, which allows for a more targeted anticancer effect. The pharmacokinetics of doxifluridine and its active metabolite, 5-FU, are crucial for its antitumor activity and toxicity profile.
+Doxifluridine is administered orally and is absorbed through the gastrointestinal tract. Once absorbed, it is converted into 5-fluorouracil in the liver and tumor tissues. The conversion process is facilitated by the presence of thymidine phosphorylase, which is more abundant in tumor cells, thus providing a targeted approach to chemotherapy.
-==Adverse Effects==
-The adverse effects of doxifluridine are similar to those of 5-FU and include [[myelosuppression]], characterized by decreased white blood cell, red blood cell, and platelet counts, which increases the risk of infection, anemia, and bleeding. Other common side effects include [[nausea]], [[vomiting]], [[diarrhea]], and [[mucositis]]. Due to its mechanism of action, doxifluridine can also cause hand-foot syndrome, a condition characterized by redness, swelling, and pain on the palms of the hands and the soles of the feet.
-==Contraindications==
+==Clinical Use==
-Doxifluridine is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should also be used with caution in patients with severe renal or hepatic impairment, as these conditions can affect the drug's metabolism and excretion, potentially leading to increased toxicity.
+Doxifluridine is primarily used in the treatment of [[colorectal cancer]], [[breast cancer]], and [[gastric cancer]]. It is often used in combination with other chemotherapeutic agents to enhance its efficacy. The drug's ability to be selectively activated in tumor tissues makes it a valuable option in cancer therapy.
-==Drug Interactions==
+==Side Effects==
-Doxifluridine can interact with other medications that affect DNA and RNA synthesis, such as other chemotherapeutic agents, which may enhance both its therapeutic effects and toxicity. It is important to closely monitor patients for adverse effects when doxifluridine is used in combination with other drugs.
+As with many chemotherapeutic agents, doxifluridine can cause a range of side effects. Common side effects include [[nausea]], [[vomiting]], [[diarrhea]], and [[myelosuppression]]. Due to its selective activation, it may have a more favorable side effect profile compared to direct administration of 5-fluorouracil.
-==Conclusion==
+==Related pages==
-Doxifluridine represents an important option in the treatment of certain cancers, offering the potential for targeted therapy with its prodrug design. However, its use requires careful consideration of its pharmacokinetics, potential adverse effects, and interactions with other medications to optimize patient outcomes.
+* [[5-fluorouracil]]
+* [[Chemotherapy]]
+* [[Cancer treatment]]
-[[Category:Cancer treatment]]
+[[Category:Chemotherapeutic agents]]
-[[Category:Chemotherapy agents]]
 [[Category:Prodrugs]]
-{{Chemotherapy}}
-{{Antineoplastic agents}}
-{{medicine-stub}}